ELUT

Elutia Inc.
CAPPED RATING

Elutia Inc. (ELUT) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (A-); its weakest is Growth (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
F
Factor Score 0.6 / 5.0
Profitability
A-
Factor Score 3.9 / 5.0
Momentum
C+
Factor Score 2.8 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.8
EV / EBITDA -0.9
Rev Growth YoY -65.8%
Gross Margin 57.7%
Price Return 3M 14.1%
Price Return 12M 4.3%
Catalyst Signal 0.00
Market Cap $41.3M
TTM Revenue $13.6M
Price / Sales 3.0
ROE N/A

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B- (3.0) F (0.6) A- (3.9) C+ (2.8) C+ (2.6) C+ (2.6)
2026-11-04 B- (3.0) D (1.2) B (3.3) C+ (2.6) C+ (2.7) C+ (2.5)
2026-10-28 B- (3.0) D (1.2) B (3.3) C (2.3) C+ (2.7) C (2.5)
2026-10-21 B- (3.0) D (1.2) B (3.3) C- (2.1) C+ (2.6) C (2.4)
2026-10-14 B- (3.0) D- (1.1) B (3.3) C- (1.9) C+ (2.6) C (2.4)
Page 1 of 4